Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.
Barber PR, Mustapha R, Flores-Borja F, Alfano G, Ng K, Weitsman G, Dolcetti L, Suwaidan AA, Wong F, Vicencio JM, Galazi M, Opzoomer JW, Arnold JN, Thavaraj S, Kordasti S, Doyle J, Greenberg J, Dillon MT, Harrington KJ, Forster M, Coolen ACC, Ng T. Barber PR, et al. Among authors: ng k, ng t. Elife. 2022 Dec 23;11:e73288. doi: 10.7554/eLife.73288. Elife. 2022. PMID: 36562609 Free PMC article.
HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V, Galazi M, Weitsman G, Monypenny J, Al-Salemee F, Barber PR, Ng K, Beatson R, Szokol B, Orfi L, Mullen G, Vanhaesebroeck B, Chowdhury S, Leung HY, Ng T. Gómez V, et al. Among authors: ng k, ng t. Mol Cancer Ther. 2022 Apr 1;21(4):667-676. doi: 10.1158/1535-7163.MCT-21-0320. Mol Cancer Ther. 2022. PMID: 35086953 Free PMC article.
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.
Vicencio JM, Evans R, Green R, An Z, Deng J, Treacy C, Mustapha R, Monypenny J, Costoya C, Lawler K, Ng K, De-Souza K, Coban O, Gomez V, Clancy J, Chen SH, Chalk A, Wong F, Gordon P, Savage C, Gomes C, Pan T, Alfano G, Dolcetti L, Chan JNE, Flores-Borja F, Barber PR, Weitsman G, Sosnowska D, Capone E, Iacobelli S, Hochhauser D, Hartley JA, Parsons M, Arnold JN, Ameer-Beg S, Quezada SA, Yarden Y, Sala G, Ng T. Vicencio JM, et al. Among authors: ng k, ng t. Cell Death Dis. 2022 Mar 28;13(3):274. doi: 10.1038/s41419-022-04701-3. Cell Death Dis. 2022. PMID: 35347108 Free PMC article.
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Ng K, Metcalf R, Sacco J, Kong A, Wheeler G, Forsyth S, Bhat R, Ward J, Ensell L, Lowe H, Spanswick V, Hartley J, White L, Lloyd-Dehler E, Forster M. Ng K, et al. BMJ Open. 2023 Nov 27;13(11):e070391. doi: 10.1136/bmjopen-2022-070391. BMJ Open. 2023. PMID: 38011968 Free PMC article.
Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis.
Pemberton L, Ng K, McGovern U, Macdonald A, Barot H, Galazi M, Wilson P, Wells P, Linch M, Alifrangis C, Shamash J. Pemberton L, et al. Among authors: ng k. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):166-168. doi: 10.1038/s41391-020-0261-z. Epub 2020 Jul 24. Prostate Cancer Prostatic Dis. 2021. PMID: 32709977 No abstract available.
5,240 results